研究業績

Publications

Goto H, Shiraishi Y, Okada S. Continuing progress in radioimmunotherapy for hematologic malignancies. Blood Rev. 69, 101250 (2025)

Goto H, Kariya R, Kudo E, Katano H, Okada S. PAX5 functions as a tumor suppressor by RB-E2F-mediated cell cycle arrest in Kaposi sarcoma-associated herpesvirus-infected primary effusion lymphoma. Neoplasia. 56, 101035 (2024)

Goto H, Shiraishi Y, Okada S. Performance Evaluation of Generative Pretrained Transformer-4o and o1-preview using the Certification Examination for the Japanese ’Operations Chief of Radiography with X-rays’. Cureus. 16(11), e74262 (2024)

Goto H, Shiraishi Y, Okada S. Performance of Generative Pre-trained Transformer (GPT)-4 and Gemini Advanced on the First-Class Radiation Protection Supervisor Examination in Japan. Cureus. 16(10), e70614 (2024)

Goto H, Shiraishi Y, Okada S. Recent preclinical and clinical advances in radioimmunotherapy for non-Hodgkin’s lymphoma. Explor Target Antitumor Ther. 5, 208-224 (2024)

Jasra S, Giricz O, Zeig-Owens R, Pradhan K, Goldfarb DG, Barreto-Galvez A, Silver AJ, Chen J, Sahu S, Gordon-Mitchell S, Choudhary GS, Aluri S, Bhagat TD, Shastri A, Bejan C., Stockton SS, Spaulding TP, Thiruthuvanathan V, Goto H, Gerhardt J, Haider SH, Veerappan A, Bartenstein M, Nwankwo G, Landgren O, Weiden MD, Lekostaj J, Bender R, Fletcher F, Greenberger L, Ebert BL, Steidl U, Will B, Nolan A, Madireddy A, Savona MR, Prezant DJ, Verma A. High burden of clonal Hematopoiesis in first responders exposed to the World Trade Center disaster. Nat Med. 28, 468-471 (2022)

Ueda K, Kumari R, Schwenger E, Wheat JC, Bohorquez O, Narayanagari SR, Taylor SJ, Carvajal LA, Pradhan K, Bartholdy B, Todorova TI, Goto H, Sun D, Chen J, Shan J, Song Y, Montagna C, Xiong S, Lozano G, Pellagatti A, Boultwood J, Verma A, Steidl U. MDMX acts as a pervasive preleukemic-to-acute myeloid leukemia transition mechanism. Cancer Cell. 39(4), 529-547 (2021)

Goto H, Nishio M, To Y, Oishi T, Miyachi Y, Maehama T, Nishina H, Akiyama H, Mak TW, Makii Y, Saito T, Yasoda A, Tsumaki N, Suzuki A. Loss of Mob1a/b in mice results in chondrodysplasia due to YAP1/TAZ-TEADs-dependent repression of SOX9. Development. 145(6), dev159244 (2018)

Kudo E, Manabu T, Suico MA, Goto H, Hirohumi K, Okada S. Transcriptional regulation of HIV-1 host factor COMMD1 by the Sp family. Int J Mol Med. 41(4), 2366-2374 (2018)

Nishio M, Maehama T, Goto H, Nakatani K, Kato W, Omori H, Miyachi Y, Togashi H, Shimono Y, Suzuki A. Hippo vs. Crab: tissue-specific functions of the mammalian Hippo pathway. Genes Cells. 22(1), 6-31 (2017)

Nakatani K, Maehama T, Nishio M, Goto H, Kato W, Omori H, Miyachi Y, Togashi H, Shimono Y, Suzuki A. Targeting the Hippo Signaling Pathway for Cancer Treatment. J Biochem. 161(3), 237-244 (2017)

Goto H, Kariya R, Kudo E, Okuno Y, Ueda K, Katano H, Okada S. Restoring PU.1 induces apoptosis and modulates viral transactivation via interferon-stimulated genes in primary effusion lymphoma. Oncogene. 36(37), 5252-5262 (2017)

Otsubo K#, Goto H# (#equal contribution), Nishio M, Kawamura K, Yanagi S, Nishie W, Sasaki T, Maehama T, Nishina H, Mimori K, Nakano T, Shimizu H, Mak TW, Nakao K, Nakanishi Y, Suzuki A. MOB1-YAP1/TAZ-NKX2.1 axis controls bronchioalveolar cell differentiation, adhesion and tumour formation. Oncogene. 36(29), 4201-4211 (2017)

Goto H, Kariya R, Matsuda K, Kudo E, Katano H, Okada S. A potential role of the NOD genetic background in mouse peritoneal macrophages for the development of primary effusion lymphoma. Leuk Res. 42, 37-42 (2016)

Nishio M, Sugimachi K, Goto H, Wang J, Morikawa T, Miyachi Y, Takano Y, Hikasa H, Itoh T, Suzuki SO, Kurihara H, Aishima S, Leask A, Sasaki T, Nakano T, Nishina H, Nishikawa Y, Sekido Y, Nakao K, Shin-Ya K, Mimori K, Suzuki A. Dysregulated YAP1/TAZ and TGF-β signaling mediate hepatocarcinogenesis in Mob1a/1b-deficient mice. Proc Natl Acad Sci U S A. 113(1), E71-80 (2016)

Nishio M, Goto H, Suzuki M, Fujimoto A, Mimori K, Suzuki A. The Hippo Signaling Pathway: A Candidate New Drug Target for Malignant Tumors. Innovative Medicine: Basic Research and Development, p.79-94 (2015)

Ohkuma K, Matsuda K, Kariya R, Goto H, Kamei S, Hamamoto T, Okada S. Anti-inflammatory effects of activated protein C on human dendritic cells. Microbiol Immunol. 59(7), 381-388 (2015)

Matsuda K, Hattori S, Kariya R, Komizu Y, Kudo E, Goto H, Taura M, Ueoka R, Kimura S, Okada S. Inhibition of HIV-1 entry by the tricyclic coumarin GUT-70 through the modification of membrane fluidity. Biochem Biophys Res Commun. 457(3), 288-294 (2015)

Taura M, Kudo E, Kariya R, Goto H, Matsuda K, Hattori S, Vaeteewoottacharn K, McDonald F, Suico MA, Shuto T, Kai H, Okada S. COMMD1/Murr1 reinforces HIV-1 latent infection through IκB-α stabilization. J Virol. 89(5), 2643-2658 (2015)

Goto H, Kudo E, Kariya R, Taura M, Katano H, Okada S. Targeting VEGF and interleukin-6 for controlling malignant effusion of primary effusion lymphoma. J Cancer Res Clin Oncol. 141(3), 465-474 (2015)

Okada S, Goto H, Yotsumoto M. Current status of treatment for primary effusion lymphoma. Intractable Rare Dis Res. 3, 65-74 (2014)

Goto H, Kojima Y, Matsuda K, Kariya R, Taura M, Kuwahara K, Nagai H, Katano H, Okada S. Efficacy of anti-CD47 antibody-mediated phagocytosis with macrophages against primary effusion lymphoma. Eur J Cancer 50(10), 1836-1846 (2014)

Goto H, Okada S. New approaches to treating Primary Effusion Lymphoma. Expert Opin Orphan Drugs 1(12), 1019-1029 (2013)

Taura M, Kariya R, Kudo E, Goto H, Iwawaki T, Amano M, Suico MA, Kai H, Mitsuya H, Okada S. Comparative analysis of ER stress response into HIV protease inhibitors: Lopinavir but not darunavir induces potent ER stress response via ROS/JNK pathway. Free Radic Biol Med. 65C, 778-788 (2013)

Goto H, Kojima Y, Nagai H, Okada S. Establishment of a CD4-positive cell line from an AIDS-related primary effusion lymphoma. Int J Hematol. 97(5), 624-633 (2013)

Suzu I, Goto H, Hiwatashi N, Hattori S, Rotjanapan K, Leeanansaksiri W, Okada S. Antioxidant and Antityrosinase Activity of Cissus quadrangularis Extract. Nat Prod Commun. 8(5), 629-630 (2013)

Goto H, Matsuda K, Srikoon P, Kariya R, Hattori S, Taura M, Katano H, Okada S. Potent antitumor activity of zoledronic acid-induced Vγ9Vδ2 T cells against primary effusion lymphoma. Cancer Lett. 331(2), 174-182 (2013)

Kudo E, Taura M, Matsuda K, Shimamoto M, Kariya R, Goto H, Hattori S, Kimura S, Okada S. Inhibition of HIV-1 replication by a tricyclic coumarin GUT-70 in acutely and chronically infected cells. Bioorg Med Chem Lett. 23(3), 606-609 (2013)

Srikoon P, Kariya R, Kudo E, Goto H, Vaeteewoottacharn K, Taura M, Wongkham S, Okada S. Diethyldithiocarbamate suppresses an NF-kappaB dependent metastatic pathway in cholangiocarcinoma cells. Asian Pac J Cancer Prev. 14, 4441-4446 (2013)

Goto H, Kariya R, Shimamoto M, Kudo E, Taura M, Katano H, Okada S. Antitumor effect of berberine against primary effusion lymphoma via inhibition of NF-κB pathway. Cancer Sci. 103(4), 775-781 (2012)

Michai M, Goto H, Hattori S, Vaeteewoottacharn K, Wongkham C, Wongkham S, Okada S. Soluble CD30: a possible serum tumor marker for primary effusion lymphoma. Asian Pac J Cancer Prev. 13, 4939-4941 (2012)

Taura M, Suico MA, Koyama K, Komatsu K, Miyakita R, Matsumoto C, Kudo E, Kariya R, Goto H, Kitajima S, Takahashi C, Shuto T, Nakao M, Okada S, Kai H. Rb/E2F1 regulates the innate immune receptor Toll-like receptor 3 in epithelial cells. Mol Cell Biol. 32(8), 1581-1590 (2012)

Goto H, Hagiwara S, Hirai R, Miyama T, Honda H, Tagashira A, Iizuka T, Mochizuki M, Teruya K, Kikuchi Y, Oka S, Miwa A. Case of relapsed AIDS-related plasmablastic lymphoma treated with autologous stem cell transplantation and highly active antiretroviral therapy. Rare Tumors. 3, e11 (2011)